Nadkarni GN et al. – This study evaluated the real–world risk of acute kidney injury (AKI) associated with the SGLT2 inhibitors in patients with type 2 diabetes (T2D) and concluded that SGLT2 inhibitors did not increase the risk of AKI in 2 large health systems.

Methods

• Longitudinal data from the Mount Sinai chronic kidney disease registry and the Geisinger Health System cohort were used for this study analysis.
• Study population were selected to include SGLT2 inhibitor users and nonusers in 1:1 ratio.

Results

• An AKIKDIGO event occurred in 3.8% and 2.2% of users and in 9.7% and 4.6% of nonusers in the Mount Sinai cohort and Geisinger cohort, respectively.
• Use of SGLT2 inhibitor reduced the risk of an AKI by 50% to 60% compared with nonusers as suggested by the unadjusted hazard ratios.